Brad Watts, senior vice president at the U.S. Chamber of Commerce’s Global Innovation Policy Center (GIPC), oversees the center’s day-to-day operations. He also leads the development and implementation of the Chamber’s U.S. and global intellectual property (IP) agenda to foster a political, legal, and economic environment where innovators and creators can invest in the next big thing for the benefit of Americans and the world.
Watts previously served as the Republican chief counsel on the Senate Judiciary Committee Subcommittee on Intellectual Property. There he was responsible for planning and implementing Senator Thom Tillis’ (R-NC) and the Republican party’s legislative portfolio on all aspects of IP law.
In the 116th Congress, when Senator Tillis was chairman of the subcommittee, Watts served as majority chief counsel and staff director for the Senate Judiciary Committee Subcommittee on Intellectual Property. He was responsible for implementing the senator’s legislative and oversight agenda on all aspects of America’s innovation economy.
During Watts’ tenure as majority chief counsel, the subcommittee held 17 legislative and oversight hearings and multiple staff briefings on IP issues, ranging from the state of patent eligibility law in America to reforming the Digital Millennium Copyright Act of 1998. Under his leadership, the subcommittee passed the CASE Act, the Trademark Modernization Act, and the Protecting Lawful Streaming Act, three landmark bills that collectively represent the largest changes to IP law since the Leahy-Smith America Invents Act.
Earlier, Watts was chief immigration counsel to then-Senate Judiciary Committee Chairman Chuck Grassley (R-IA). He began his career with former Senator Jeff Sessions (R-AL) as a legislative counsel on the Subcommittee on Immigration and the National Interest, handling civil rights and civil liberties law, general tort law, bankruptcy, telecommunications, and IP issues for the senator.
America’s AI Action Plan: Green Lights or Guardrails?
Neil Chilson, Kevin Frazier, Mario Loyola, Asad Ramzanali
America’s new AI Action Plan — announced by the White House in July and framed...
Medicare's New Drug Price Mandate: Healthcare & Innovation Implications
Lisa Larrimore Ouellette, Adam Mossoff, Dan Troy, Brad Watts
On January 17, the Biden-Harris Administration added 15 new drugs, including Ozempic, to the list of...
Does Privacy Exist in an AI World? (Part I: Rethinking Data Protection)
Ashley Baker, Pam Dixon, Kevin Frazier, Jennifer Huddleston
Join us Monday, June 9th, at 12:00pm EST for a timely discussion examining how artificial...
EEOC in the Trump Era
Eric Dreiband, Bradford J. Kelley, Ryan H. Nelson
Shortly after taking office, President Trump reportedly removed two Equal Employment Opportunity Commission (EEOC) commissioners...
Explainer Episode 89 - State Lessons for DOGE
Jonathan Wolfson, Reeve T. Bull, Patrick Price
In a little over 100 days, the Department of Government Efficiency, or "DOGE," has fundamentally...
Confronting the Questions: A Discussion on the EPA’s Proposed Revisions to Endangerment Finding
Jonathan H. Adler, Richard B. Belzer, Michael Buschbacher, Laura Stanley
Under the Clean Air Act, the Environmental Protection Agency (EPA) is required to regulate emissions...
Tech Roundup Episode 26 - Making Sense of Recent White House AI Policy
Kevin Frazier, Aram A. Gavoor
In this Tech Roundup Episode of RTP's Fourth Branch podcast, Kevin Frazier and Aram Gavoor...
Regulatory Ferment at DOL and the NLRB
Gregory Frederick Jacob, Sheng Li, Philip A. Miscimarra, Seema Nanda
In a time of rapidly shifting administrative law norms, the Department of Labor and NLRB...
Tech Roundup Episode 25 - How are the States Approaching AI?
Kevin Frazier, Dean W. Ball, Sunny Gandhi
As the second Trump administration kicks off an ambitious AI agenda, individual states have been...
Does President Trump Have the Authority to Pause and Modify the Medicare Drug Price Negotiation Program?
John Shu, Jeff Stier, Dan Troy
Since its inception, the Inflation Reduction Act’s (IRA) Medicare Drug Price Negotiation Program has been...